| abstract |
It refers to compounds of formula (I) and pharmaceutically acceptable salts thereof, where: A is N-heterocycloalkyl, NR12R13; R1 is H or C1-C7 alkyl; R2 is H, CN, among others; R3 is H, C1-C7 alkyl or C3-C8 cycloalkyl; R12 is optionally substituted heterocycloalkyl and comprising one N atom; R13 is H, C1-C7 alkyl or C3-C8 cycloalkyl. Preferred compounds are: 2- (2-methylimidazo [1,2-b] pyridazin-6-yl) -7- (4-methylpiperazin-1-yl) pyrido [1,2-a] pyrimidin-4-one; 7 - [(8aR) -3,4,6,7,8,8a-hexahydro-1H-pyrrolo [1,2-a] pyrazin-2-yl] -2- (2-methylimidazo [1,2-b ] pyridazin-6-yl) pyrido [1,2-a] pyrimidin-4-one; among others. It also refers to a process, pharmaceutical compositions, and a method. These compounds are modulators of motor neuron survival gene splicing (SMN2) being useful in the treatment of spinal muscular atrophy (SMA) |